927例CNLC Ⅰa~Ⅲa期肝细胞癌手术与预后单中心分析
回顾性分析青岛大学附属医院927例因肝细胞癌首次行肝切除术患者的临床资料,中位随访至2024年12月31日。中位总生存130.5个月,5年总生存率68.4%;CNLC Ⅰa~Ⅲa期5年总生存率分别为78.0%、63.5%、43.1%、43.6%。术后常规辅助TACE不推荐,但微血管侵犯、肿瘤最大径>5 cm或多发肿瘤患者可能获得无复发生存获益。
要点
- CNLC Ⅰa~Ⅲa期肝细胞癌术后5年总生存率分别为78.0%、63.5%、43.1%、43.6%。
- 术后常规辅助TACE不推荐,微血管侵犯、最大径>5 cm或多发肿瘤者可能DFS获益。
- 腹腔镜与开腹肝切除术在匹配后及相同CNLC分期亚组中DFS和OS无显著差异。
核心结论
- 外科治疗是肝细胞癌患者获得长期生存的重要手段。
- 肝细胞癌术后不建议常规行TACE治疗。
- 合并微血管侵犯、肿瘤最大径>5 cm或多发肿瘤的患者,术后行TACE能带来无复发生存方面的获益。
研究设计与样本
- 本研究为回顾性病例系列研究,收集青岛大学附属医院肝胆胰外科2013年1月至2020年12月连续收治的927例因肝细胞癌首次行肝切除术患者的临床资料。
- 927例中男性766例(82.6%),女性161例(17.4%),年龄(57.6±9.7)岁(范围:17~85岁)。
- 随访截至2024年12月31日,采用Kaplan-Meier法估计生存率,Log-rank检验比较不同肿瘤分期生存差异,Cox比例风险模型筛选独立预后因素。
- 比较腹腔镜与开腹肝切除术及术后辅助TACE时,采用倾向性评分匹配进行1∶1最邻近匹配,卡钳值设置为0.02。
主要发现
- 927例患者中位总生存时间为130.5个月,1、3、5、10年总体生存率分别为94.2%、79.9%、68.4%、52.3%。
- 中位无复发生存时间为37.8个月,1、3、5年无复发生存率分别为74.0%、52.0%、39.8%。
- CNLC Ⅰa期、Ⅰb期、Ⅱ期、Ⅲa期患者5年总生存率分别为78.0%、63.5%、43.1%、43.6%,5年无复发生存率分别为48.5%、35.0%、16.0%、20.1%。
- 多因素Cox分析显示性别、年龄、白蛋白、肿瘤分化程度、肿瘤数目、微血管侵犯、大血管侵犯是复发的独立预后因素(P值均<0.05);年龄、白蛋白、肿瘤分化程度、肿瘤数目、微血管侵犯、肝被膜侵犯、术中出血是生存的独立预后因素(P值均<0.05)。
- 倾向性评分匹配后,辅助TACE组与非辅助TACE组DFS及OS差异均无统计学意义(P值均>0.05);腹腔镜组与开腹组DFS及OS差异均无统计学意义(P值均>0.05),相同CNLC分期亚组中亦无显著差异(P值均>0.05)。
关键数值与推荐
- CNLC Ⅰa期、Ⅰb期、Ⅱ期、Ⅲa期患者5年总生存率分别为78.0%、63.5%、43.1%、43.6%。
- CNLC Ⅰa期、Ⅰb期、Ⅱ期、Ⅲa期患者5年无复发生存率分别为48.5%、35.0%、16.0%、20.1%。
- 经多因素Cox回归调整复发的独立预后因素后,伴有微血管侵犯、肿瘤最大径>5 cm及肿瘤数目多发的患者,术后行TACE组DFS优于未行TACE组(P值均<0.05)。
临床怎么用
- 肝细胞癌术后不建议常规行辅助TACE治疗。
- 对合并微血管侵犯、肿瘤最大径>5 cm或多发肿瘤的患者,可考虑术后辅助TACE以改善无复发生存。
- 腹腔镜与开腹肝切除术在相同CNLC分期亚组中DFS和OS无显著差异,术式选择可结合患者具体情况。
局限性
- 本研究为单中心回顾性病例系列研究。
- 比较腹腔镜与开腹手术及辅助TACE的预后影响时采用倾向性评分匹配,但仍可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the efficacy and prognosis of surgical treatment for hepatocellular carcinoma. Methods: This is a retrospective case series study. Clinical data of 927 consecutive patients who underwent initial hepatectomy for hepatocellular carcinoma(HCC) at the Department of Hepatobiliary and Pancreatic Surgery,Affiliated Hospital of Qingdao University from January 2013 to December 2020 were retrospectively collected. There were 766 males (82.6%) and 161 females (17.4%),with an age of (57.6±9.7)years (range: 17 to 85 years). Prognostic data were obtained through outpatient follow-up visits and telephone follow-up,and follow-up was continued until December 31,2024. Kaplan-Meier method was used to estimate survival rates and plot survival curves,and Log-rank test was used to compare survival differences among different tumor stages. Cox proportional hazards model was used to identify independent prognostic factors for recurrence and survival. When comparing the prognostic impact of laparoscopic versus open hepatectomy and postoperative adjuvant transcatheter arterial chemoembolization(TACE),propensity score matching was performed using 1∶1 nearest-neighbor matching with a caliper of 0.02. Results: (1) Among 927 patients,the median overall survival (OS) time was 130.5 months,and the 1-, 3-, 5-, and 10-year OS rates were 94.2%, 79.9%, 68.4%, and 52.3%, respectively. The median disease-free survival(DFS) time was 37.8 months,and the 1-, 3-, and 5-year DFS rates were 74.0%,52.0%,and 39.8%, respectively. The 5-year OS rates of patients with China Liver Cancer (CNLC) stage Ⅰa, Ⅰb, Ⅱ, and Ⅲa were 78.0%, 63.5%, 43.1%, and 43.6%,respectively,and the corresponding 5-year DFS rates were 48.5%,35.0%,16.0%,and 20.1%,respectively. (2) Univariate and multivariate Cox analyses showed that sex, age,albumin,tumor differentiation,tumor number,microvascular invasion,and macrovascular invasion were independent prognostic factors for recurrence after initial hepatectomy for HCC (all P<0.05); age, albumin, tumor differentiation, tumor number,microvascular invasion,liver capsule invasion,and intraoperative blood loss were independent prognostic factors for survival after initial hepatectomy for HCC (all P<0.05). (3) Patients were divided into an adjuvant TACE group and a non-adjuvant TACE group according to whether postoperative TACE was administered. After propensity score matching,no significant differences in DFS or OS were observed between the two groups (both P>0.05). After adjustment for independent prognostic factors for recurrence using multivariate Cox regression,patients with microvascular invasion,maximum tumor diameter>5 cm,or multiple tumors had significantly better DFS in the adjuvant TACE group than in the non-adjuvant TACE group(all P<0.05). (4) Patients were divided into laparoscopic and open surgery groups according to whether laparoscopic hepatectomy was performed. After propensity score matching,no significant differences in DFS or OS were observed between the two groups (both P>0.05). Within the same CNLC stage subgroups (stage Ⅰa,Ⅰb, Ⅱ, and Ⅲa), no significant differences in DFS or OS were observed between the laparoscopic and open surgery groups (all P>0.05). Conclusions: Surgical treatment is an important means of achieving long-term survival in patients with HCC. Routine postoperative adjuvant TACE is not recommended after hepatectomy for HCC. However,postoperative adjuvant TACE may provide DFS benefits in patients with microvascular invasion,maximum tumor diameter >5 cm, or multiple tumors. 目的: 探讨肝细胞癌外科治疗的效果及预后。 方法: 本研究为回顾性病例系列研究。收集青岛大学附属医院肝胆胰外科2013年1月至2020年12月连续收治的因肝细胞癌首次行肝切除术的927例患者的临床资料,其中男性766例(82.6%),女性161例(17.4%),年龄(57.6±9.7)岁(范围:17~85岁)。通过门诊复查及电话随访获取患者预后资料,随访截至2024年12月31日。采用Kaplan-Meier方法估计生存率并绘制生存曲线,采用Log-rank检验比较不同肿瘤分期的生存差异。采用Cox比例风险模型筛选患者复发及生存的独立预后因素。比较腹腔镜及开腹肝切除术、术后是否辅助经导管肝动脉化疗栓塞(TACE)对患者预后的影响时,采用倾向性评分匹配进行1∶1最邻近匹配、卡钳值设置为0.02。 结果: (1)927例患者的中位生存时间为130.5个月,1、3、5、10年总体生存率分别为94.2%、79.9%、68.4%、52.3%;中位复发时间为37.8个月,1、3、5年无复发生存率分别为74.0%、52.0%、39.8%。中国肝癌分期(CNLC)Ⅰa期、Ⅰb期、Ⅱ期、Ⅲa期患者的5年生存率分别为78.0%、63.5%、43.1%、43.6%,5年无复发生存率分别为48.5%、35.0%、16.0%、20.1%。(2)单因素和多因素Cox分析结果显示,性别、年龄、白蛋白、肿瘤分化程度、肿瘤数目、是否微血管侵犯、是否大血管侵犯是肝细胞癌首次肝切除术后复发的独立预后因素(P值均<0.05);年龄、白蛋白、肿瘤分化程度、肿瘤数目、是否微血管侵犯、是否肝被膜侵犯、术中是否出血是肝细胞癌首次肝切除术后生存的独立预后因素(P值均<0.05)。(3)根据术后是否行TACE治疗将患者分为两组,经倾向性评分匹配后,两组间DFS及OS的差异均无统计学意义(P值>0.05)。经多因素Cox回归调整复发的独立预后因素后,伴有微血管侵犯、肿瘤最大径>5 cm及肿瘤数目多发的患者,术后行TACE组的DFS均优于未行TACE组,差异均有统计学意义(P值均<0.05)。(4)根据患者是否行腹腔镜手术,分为腹腔镜组及开腹组,经倾向性评分匹配后,两组间在无复发生存及总体生存方面的差异均无统计学意义(P值均>0.05),在相同分期亚组中(CNLC Ⅰa期、Ⅰb期、Ⅱ期、Ⅲa期),腹腔镜组与开腹组在无复发生存及总体生存方面的差异均无统计学意义(P值均>0.05)。 结论: 肝细胞癌外科治疗是患者获得长期生存的重要手段。肝细胞癌术后不建议常规行TACE治疗,对于合并微血管侵犯、肿瘤最大径>5 cm、多发肿瘤的患者,术后行TACE能带来无复发生存方面的获益。.
引用
- Diao QX, Li ZP, Wang ZY, et al. [Single-center analysis of surgery and prognosis in 927 patients with hepatocellular carcinoma at CNLC stages Ⅰa to Ⅲa]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 42669444. doi:10.3760/cma.j.cn112139-20260127-00040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。